CA 19-9 ELISA

Key Features and Values

– Same sample type can be used across all assays to simplify inclusion into routine serology work-up
– Ready to use reagents reduces hands-on time for assay preparation
– Long shelf life cost-effective solution by reducing wastage due to expired kits
– Suitable for inclusion on automated plate systems simplifies scale-up of test volume
– Supported by a complete panel of assays for supporting treatment monitoring of several forms of cancer

Product Description

Immunoenzymatic colorimetric method for the quantitative determination of CA19-9 concentration in human serum or plasma. CA19-9 ELISA is intended for laboratory use only.

Scientific Description
CA19-9 represents the most important tumour marker of the mucin type glycoproteins group, that are associated to gastrointestinal cancer pathology.  The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues.  Recent reports indicate that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas.  Together with CEA, elevated CA19-9 is suggestive of gall bladder neoplasm in the setting of inflammatory gall bladder disease.  This tumour associated antigen may also be elevated in some non-malignant conditions.
It has been shown that a persistent elevation in serum CA19-9 value following treatment may be indicative of occult metastatic and/or residual disease.  Research studies demonstrate that serum CA19-9 values may have utility in monitoring subjects with the above mentioned diagnosed malignancies.  A persistently rising serum CA19-9 value may be associated with progressive malignant disease and poor therapeutic response.  A declining CA19-9 value may be indicative of a favourable prognosis and good response to treatment.
Publications

1. Glenn J., et al J. Clin. Oncol. 6:462-8 (1988)
2. Hayakawa T., et al Cancer 61:1827-31 (1988)
3. Koprowski H., et al Science 212:53-5 (1981)
4. Malesci A., et al Gastroenteroglogy 92:60-7 (1987)
5. Safi F, et al Pancreas 2:398-403 (1987)
6. Steinberg W. Am J. of Gastroenterology 85:350-355 (1990)
7. Steinberg W.M., et al Gastroenterology 90:343-9 (1986)
8. Takasaki H., et al Cancer Res. 48:1435-8 (1988)
9. Tatsuta M., et al Cancer 56:2669-73 (1985)
10.Wang T.H. et al Pancreas 1:219-23 (1986)
11.Strom BL, et al Int. J. Cancer 45:821 (1990)

Download
Please enter your email address to download the DKO056 - CA 19-9 - IFU.pdf
Code: DKO056
Clinical Area:
Incubation: 60+60+15 min
Classification: IVD, CE
Number of Tests: 96
Sample Type: Serum/Plasma
Sample Volume: 100 μL
Assay Range: 15 -240 U/mL